文献速递艾滋病与性传播感染真菌感染

人类免疫缺陷病毒感染者的隐球菌脑膜炎与临床结局:全球视角

Cryptococcal Meningitis and Clinical Outcomes in Persons With Human Immunodeficiency Virus: A Global View.
PubMed 文献 · Clin Infect Dis · 2023-01-01

这项回顾性队列研究利用国际艾滋病流行病学数据库1996至2017年数据,分析518852例人类免疫缺陷病毒感染者中3857例隐球菌脑膜炎的发病率与病死率;隐球菌脑膜炎诊断后随访中位2.6年病死率31.6%,64%病例在启动抗逆转录病毒治疗后发生,89个站点中34%可获取两性霉素B、12%可获取氟胞嘧啶。

要点

  • 隐球菌脑膜炎估算发病率为1.54/1000人年,诊断后随访中位2.6年病死率31.6%。
  • 2478例(64%)在启动抗逆转录病毒治疗后诊断隐球菌脑膜炎,中位间隔253天。
  • 89个站点中34%报告可获取两性霉素B,12%可获取氟胞嘧啶。

核心结论

  • 隐球菌脑膜炎诊断后病死率高。
  • 相当一部分隐球菌脑膜炎病例发生在启动抗逆转录病毒治疗后,但发病率与病死率可能因确认偏倚而高于报告值。
  • 许多站点缺乏推荐隐球菌脑膜炎治疗的可及性。

研究设计与样本

  • 回顾性队列研究,利用国际艾滋病流行病学数据库评估1996至2017年人类免疫缺陷病毒感染者的隐球菌脑膜炎发病率与全因病死率。
  • 采用准泊松模型估算发病率,调整性别、年龄、日历年、CD4细胞计数和抗逆转录病毒治疗状态。
  • 采用多变量Cox模型分析隐球菌脑膜炎诊断后病死率;2017年站点调查评估隐球菌脑膜炎诊断与治疗方式的可及性。
  • 共纳入518852例人类免疫缺陷病毒感染者,其中3857例隐球菌脑膜炎。

主要发现

  • 隐球菌脑膜炎估算发病率为1.54/1000人年。
  • 隐球菌脑膜炎诊断后随访中位2.6年,病死率31.6%,失访率29%。
  • 2478例(64%)在启动抗逆转录病毒治疗后诊断隐球菌脑膜炎,从启动抗逆转录病毒治疗至诊断隐球菌脑膜炎的中位时间为253天。
  • 年龄较大(50岁 vs 35岁,HR 1.31)、CD4较低(200 vs 350 cells/mm3,HR 1.15)和隐球菌脑膜炎诊断年份较早(2015年 vs 2000年,HR 0.51)与较高病死率相关。
  • 89个站点中,34%报告可获取两性霉素B;12%可获取氟胞嘧啶。

局限性

  • 发病率与病死率可能因确认偏倚而高于报告值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cryptococcal meningitis (CM) is a major cause of morbidity and mortality in persons with human immunodeficiency virus (HIV; PWH). Little is known about CM outcomes and availability of diagnostic and treatment modalities globally. METHODS: In this retrospective cohort study, we investigated CM incidence and all-cause mortality in PWH in the International Epidemiology Databases to Evaluate AIDS cohort from 1996 to 2017. We estimated incidence using quasi-Poisson models adjusted for sex, age, calendar year, CD4 cell count (CD4), and antiretroviral therapy (ART) status. Mortality after CM diagnosis was examined using multivariable Cox models. A site survey from 2017 assessed availability of CM diagnostic and treatment modalities. RESULTS: Among 518 852 PWH, there were 3857 cases of CM with an estimated incidence of 1.54 per 1000 person-years. Mortality over a median of 2.6 years of post-CM diagnosis follow-up was 31.6%, with 29% lost to follow-up. In total, 2478 (64%) were diagnosed with CM after ART start with a median of 253 days from ART start to CM diagnosis. Older age (hazard [HR], 1.31 for 50 vs 35 years), lower CD4 (HR, 1.15 for 200 vs 350 cells/mm3), and earlier year of CM diagnosis (HR, 0.51 for 2015 vs 2000) were associated with higher mortality. Of 89 sites, 34% reported access to amphotericin B; 12% had access to flucytosine. CONCLUSIONS: Mortality after CM diagnosis was high. A substantial portion of CM cases occurred after ART start, though incidence and mortality may be higher than reported due to ascertainment bias. Many sites lacked access to recommended CM treatment.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Person AK, Crabtree-Ramirez B, Kim A, et al. Cryptococcal Meningitis and Clinical Outcomes in Persons With Human Immunodeficiency Virus: A Global View. Clin Infect Dis. 2023. PMID: 36821489. doi:10.1093/cid/ciad076

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。